JEWJITSU PEPTIDES News Roundup: Diabetes, Muscle Intake, and PTH Signaling

A narrative review examines the relationship between type 2 diabetes (T2D) and cognitive decline, noting that people with T2D have higher risk of progression from mild cognitive impairment to Alzheimer’s disease and that brain insulin resistance is implicated in this conversion. The authors summarize preclinical and clinical findings that glucose‑lowering classes such as GLP‑1 receptor agonists (GLP‑1RAs) and SGLT2 inhibitors show neuroprotective signals in models and some trials, and they describe candidate mechanisms including anti‑inflammatory effects, modulation of insulin signaling, and promotion of neurogenesis. The review emphasizes that while early results are promising, translation to clinical practice requires larger randomized controlled trials with longer follow‑up, standardized cognitive endpoints, and incorporation of molecular and imaging biomarkers to address current limitations in the evidence base.

A second review focuses on the nutritional consequences of incretin‑based therapies (GLP‑1 and dual GIP/GLP‑1 receptor agonists) for older adults at risk of sarcopenia. These agents induce weight loss largely via reduced appetite and calorie intake; the review highlights concerns that absolute protein intake can fall even when the proportion of energy from protein is preserved. The authors report randomized trial data for liraglutide indicating proportional protein intake values in a reported range, but they caution that reductions in total energy may reduce absolute protein below amounts needed to stimulate muscle protein synthesis in older people. They note limited comprehensive dietary data and a lack of long‑term trials that combine detailed intake assessment with body composition and functional outcomes, calling for studies that clarify whether observed intake changes translate into clinically meaningful muscle loss.

A third review addresses recent reclassification of skeletal dysplasias that groups disorders by disrupted parathyroid hormone (PTH) signaling. It covers genetic defects affecting PTH, PTH‑related protein (PTHrP, encoded by PTHLH), and the common receptor PTH1R, as well as overlapping defects in the Gsα subunit and downstream effectors. The review explains that PTH and PTHrP can exert both catabolic and anabolic effects on bone and that PTHrP normally inhibits chondrocyte maturation. The authors describe phenotypic patterns tied to signaling level: increased cascade signaling can produce osteolysis with focal osteosclerosis or delayed growth‑plate ossification, partial loss may present as type E brachydactyly or pseudohypoparathyroidism, and total loss is associated with osteosclerosis and markedly accelerated bone maturation as in Blomstrand dysplasia. The paper frames these findings within nosology and molecular mechanism discussions rather than as clinical treatment recommendations.